MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581686 | Name: Dexamethason 21-tert-butylacetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dexamethason 21-tert-butylacetate is a biochemical.

Chemical Structure

Dexamethason 21-tert-butylacetate
Dexamethason 21-tert-butylacetate
CAS#24668-75-5

Theoretical Analysis

MedKoo Cat#: 581686

Name: Dexamethason 21-tert-butylacetate

CAS#: 24668-75-5

Chemical Formula: C28H39FO6

Exact Mass: 490.2731

Molecular Weight: 490.61

Elemental Analysis: C, 68.55; H, 8.01; F, 3.87; O, 19.57

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Dexamethason 21-tert-butylacetate; Dexamethasone tert-butylacetate; Decadron TBA.
IUPAC/Chemical Name
9-Fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 21-(3,3-dimethylbutyrate)
InChi Key
PQVDYPCHUGFHAR-PKWREOPISA-N
InChi Code
InChI=1S/C28H39FO6/c1-16-11-20-19-8-7-17-12-18(30)9-10-25(17,5)27(19,29)21(31)13-26(20,6)28(16,34)22(32)15-35-23(33)14-24(2,3)4/h9-10,12,16,19-21,31,34H,7-8,11,13-15H2,1-6H3/t16-,19+,20+,21+,25+,26+,27+,28+/m1/s1
SMILES Code
C[C@@]12[C@](C(COC(CC(C)(C)C)=O)=O)(O)[C@H](C)C[C@@]1([H])[C@]3([H])CCC4=CC(C=C[C@]4(C)[C@@]3(F)[C@@H](O)C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 490.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, Gavriatopoulou M, Christoulas D, Ntanasis-Stathopoulos I, Kourakli A, Konstantinidou P, Kastritis E, Dimopoulos MA. Effect of induction therapy with lenalidomide, doxorubicin, and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32125. [Epub ahead of print] PubMed PMID: 30650184. 2: Aru M, Alev K, Pehme A, Purge P, Onnik L, Ellam A, Kaasik P, Seene T. Changes in Body Composition of Old Rats at Different Time Points after Dexamethasone Administration. Curr Aging Sci. 2019 Jan 14. doi: 10.2174/1874609812666190114144238. [Epub ahead of print] PubMed PMID: 30648531. 3: Wang J, Li Y, Wang C, Zhang Y, Gao C, Lang H, Chen X. Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis. Biomed Res Int. 2018 Dec 12;2018:1316096. doi: 10.1155/2018/1316096. eCollection 2018. Review. PubMed PMID: 30648105; PubMed Central PMCID: PMC6311778. 4: Torres-López L, Maycotte P, Liñán-Rico A, Liñán-Rico L, Donis-Maturano L, Delgado-Enciso I, Meza-Robles C, Vásquez-Jiménez C, Hernández-Cruz A, Dobrovinskaya O. Tamoxifen induces toxicity, causes autophagy, and partially reverses dexamethasone resistance in Jurkat T cells. J Leukoc Biol. 2019 Jan 15. doi: 10.1002/JLB.2VMA0818-328R. [Epub ahead of print] PubMed PMID: 30645008. 5: Li S, Meng XY, Maman STD, Xiao YN, Li S. Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data. Biomed Res Int. 2018 Dec 16;2018:9057823. doi: 10.1155/2018/9057823. eCollection 2018. PubMed PMID: 30643823; PubMed Central PMCID: PMC6311249. 6: Reynolds SB, Hashmi H, Ngo P, Kloecker G. Rescue therapy for acute idiopathic thrombocytopenic purpura unresponsive to conventional treatment. BMJ Case Rep. 2019 Jan 14;12(1). pii: bcr-2018-227717. doi: 10.1136/bcr-2018-227717. PubMed PMID: 30642865. 7: Yasuda S, Najima Y, Konishi T, Yamada Y, Takezaki T, Kurosawa S, Sakaguchi M, Harada K, Yoshioka K, Igarashi A, Inamoto K, Toya T, Kobayashi T, Doki N, Kakihana K, Sakamaki H, Sekiya N, Ohashi K. Disseminated adenovirus infection in a patient with relapsed refractory multiple myeloma undergoing autologous stem cell transplantation and pomalidomide/dexamethasone as salvage regimens. J Infect Chemother. 2019 Jan 11. pii: S1341-321X(18)30469-0. doi: 10.1016/j.jiac.2018.11.011. [Epub ahead of print] PubMed PMID: 30642772. 8: Yoshida N, Taguchi T, Nakanishi M, Inoue K, Okayama T, Ishikawa T, Otsuji E, Takayama K, Kuroboshi H, Kanazawa M, Itoh Y. Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. BMC Pharmacol Toxicol. 2019 Jan 14;20(1):6. doi: 10.1186/s40360-018-0278-2. PubMed PMID: 30642399. 9: Xia T, Dong X, Jiang Y, Lin L, Dong Z, Shen Y, Xin H, Zhang Q, Qin L. Metabolomics Profiling Reveals Rehmanniae Radix Preparata Extract Protects against Glucocorticoid-Induced Osteoporosis Mainly via Intervening Steroid Hormone Biosynthesis. Molecules. 2019 Jan 11;24(2). pii: E253. doi: 10.3390/molecules24020253. PubMed PMID: 30641909. 10: Nielsen T, Kristensen SR, Gregersen H, Teodorescu EM, Christiansen G, Pedersen S. Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma. PLoS One. 2019 Jan 14;14(1):e0210835. doi: 10.1371/journal.pone.0210835. eCollection 2019. PubMed PMID: 30640949. 11: Bravo D, Aliste J, Layera S, Fernández D, Leurcharusmee P, Samerchua A, Tangjitbampenbun A, Watanitanon A, Arnuntasupakul V, Tunprasit C, Gordon A, Finlayson RJ, Tran Q. A multicenter, randomized comparison between 2, 5, and 8 mg of perineural dexamethasone for ultrasound-guided infraclavicular block. Reg Anesth Pain Med. 2019 Jan;44(1):46-51. doi: 10.1136/rapm-2018-000032. PubMed PMID: 30640652. 12: Patel P, Paw Cho Sing E, Dupuis LL. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis. Expert Opin Drug Saf. 2019 Jan 14. doi: 10.1080/14740338.2019.1568988. [Epub ahead of print] PubMed PMID: 30640557. 13: Al-Khersan H, Hariprasad SM, Salehi-Had H. Dexamethasone and Anti-VEGF Combination Therapy for the Treatment of Diabetic Macular Edema. Ophthalmic Surg Lasers Imaging Retina. 2019 Jan 1;50(1):4-7. doi: 10.3928/23258160-20181212-01. PubMed PMID: 30640389. 14: Briceño-Pérez C, Reyna-Villasmil E, Vigil-De-Gracia P. Antenatal corticosteroid therapy: Historical and scientific basis to improve preterm birth management. Eur J Obstet Gynecol Reprod Biol. 2019 Jan 6;234:32-37. doi: 10.1016/j.ejogrb.2018.12.025. [Epub ahead of print] Review. PubMed PMID: 30639954. 15: Gupta VK, Brauneis D, Shelton AC, Quillen K, Sarosiek S, Sloan JM, Sanchorawala V. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for AL Amyloidosis: Long Term Follow-Up Analysis. Biol Blood Marrow Transplant. 2019 Jan 10. pii: S1083-8791(19)30015-1. doi: 10.1016/j.bbmt.2019.01.007. [Epub ahead of print] PubMed PMID: 30639823. 16: Breshears JD, Haddad AF, Viner J, Rau J, Sankaran S, McDermott MW. A Reduced Exogenous Steroid Taper (REST) for postoperative brain tumor patients - a case-control study. World Neurosurg. 2019 Jan 10. pii: S1878-8750(19)30043-9. doi: 10.1016/j.wneu.2018.12.173. [Epub ahead of print] PubMed PMID: 30639502. 17: Tajbakhsh A, Gheibi Hayat SM, Butler AE, Sahebkar A. Effect of soluble cleavage products of important receptors/ligands on efferocytosis: Their role in inflammatory, autoimmune and cardiovascular disease. Ageing Res Rev. 2019 Jan 9;50:43-57. doi: 10.1016/j.arr.2019.01.007. [Epub ahead of print] Review. PubMed PMID: 30639340. 18: Lichtblau M, Furian M, Aeschbacher SS, Bisang M, Ulrich S, Saxer S, Sheraliev U, Marazhapov NH, Osmonov B, Estebesova B, Sooronbaev T, Bloch KE, Ulrich S. Dexamethasone improves pulmonary hemodynamics in COPD-patients going to altitude: A randomized trial. Int J Cardiol. 2018 Dec 28. pii: S0167-5273(18)35017-4. doi: 10.1016/j.ijcard.2018.12.052. [Epub ahead of print] PubMed PMID: 30638985. 19: Mohan MC, Abhimannue AP, Kumar BP. Modulation of proinflammatory cytokines and enzymes by polyherbal formulation Guggulutiktaka ghritam. J Ayurveda Integr Med. 2019 Jan 10. pii: S0975-9476(18)30067-6. doi: 10.1016/j.jaim.2018.05.007. [Epub ahead of print] PubMed PMID: 30638916. 20: Croci S, Bonacini M, Muratore F, Caruso A, Fontana A, Boiardi L, Soriano A, Cavazza A, Cimino L, Belloni L, Perry O, Fridkin M, Parmeggiani M, Blank M, Shoenfeld Y, Salvarani C. The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. J Autoimmun. 2019 Jan 9. pii: S0896-8411(18)30549-3. doi: 10.1016/j.jaut.2019.01.002. [Epub ahead of print] PubMed PMID: 30638709.

View History

Rinderine

Rinderine

Featured